Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 106

1.

Is Neuronal Histamine Signaling Involved in Cancer Cachexia? Implications and Perspectives.

Zwickl H, Zwickl-Traxler E, Pecherstorfer M.

Front Oncol. 2019 Dec 20;9:1409. doi: 10.3389/fonc.2019.01409. eCollection 2019.

2.

Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trial.

Egle A, Melchardt T, Obrtlíková P, Smolej L, Kozák T, Steurer M, Andel J, Burgstaller S, Mikušková E, Gercheva L, Nösslinger T, Papajík T, Ladická M, Girschikofsky M, Hrubiško M, Jäger U, Voskova D, Pecherstorfer M, Králiková E, Burcoveanu C, Spasov E, Petzer A, Mihaylov G, Raynov J, Oexle H, Zabernigg A, Flochová E, Palášthy S, Stehlíková O, Doubek M, Altenhofer P, Weiss L, Magnes T, Pleyer L, Klingler A, Mayer J, Greil R.

Cancer Med. 2019 Apr;8(4):1401-1405. doi: 10.1002/cam4.1980. Epub 2019 Mar 19.

3.

Rationally derived drug combinations with the novel Mcl-1 inhibitor EU-5346 in breast cancer.

Vallet S, Fan F, Malvestiti S, Pecherstorfer M, Sattler M, Schneeweiss A, Schulze-Bergkamen H, Opferman JT, Cardone MH, Jäger D, Podar K.

Breast Cancer Res Treat. 2019 Feb;173(3):585-596. doi: 10.1007/s10549-018-5022-5. Epub 2018 Oct 29.

PMID:
30374681
4.

Myeloma Bone Disease: Update on Pathogenesis and Novel Treatment Strategies.

Vallet S, Filzmoser JM, Pecherstorfer M, Podar K.

Pharmaceutics. 2018 Oct 24;10(4). pii: E202. doi: 10.3390/pharmaceutics10040202. Review.

5.

Tolerability of obinutuzumab therapy in patients with rituximab-relapsed/refractory B-cell malignancies - a retrospective single center cohort study.

Pirich T, Zwickl-Traxler E, Pecherstorfer M, Singer J.

Oncotarget. 2018 Jul 6;9(52):29944-29956. doi: 10.18632/oncotarget.25714. eCollection 2018 Jul 6.

6.

Evaluation of vascular events in patients with myeloproliferative syndromes and mutations of either the januskinase-2 or calreticulin gene at the university hospital Krems from 2008 to 2015.

Hintermair S, Zwickl-Traxler E, Pecherstorfer M, Singer J.

Oncotarget. 2018 Jan 3;9(9):8450-8462. doi: 10.18632/oncotarget.23879. eCollection 2018 Feb 2.

7.

A role for bone turnover markers β-CrossLaps (CTX) and amino-terminal propeptide of type I collagen (PINP) as potential indicators for disease progression from MGUS to multiple myeloma.

Vallet S, Hoyle NR, Kyle RA, Podar K, Pecherstorfer M.

Leuk Lymphoma. 2018 Oct;59(10):2431-2438. doi: 10.1080/10428194.2017.1421757. Epub 2018 Jan 18.

PMID:
29345175
8.

Symptomatic treatment of dyspnea in advanced cancer patients : A narrative review of the current literature.

Strieder M, Pecherstorfer M, Kreye G.

Wien Med Wochenschr. 2018 Oct;168(13-14):333-343. doi: 10.1007/s10354-017-0600-4. Epub 2017 Sep 18. Review.

PMID:
28921042
9.

Adoptive cell therapy in multiple Myeloma.

Vallet S, Pecherstorfer M, Podar K.

Expert Opin Biol Ther. 2017 Dec;17(12):1511-1522. doi: 10.1080/14712598.2017.1375095. Epub 2017 Sep 6. Review.

PMID:
28857616
10.

Single-Agent Oral Vinorelbine as First-Line Chemotherapy for Endocrine-Pretreated Breast Cancer With Bone Metastases and No Visceral Involvement: NORBREAST-228 Phase II Study.

Steger GG, Dominguez A, Dobrovolskaya N, Giotta F, Tubiana-Mathieu N, Pecherstorfer M, Ardizzoia A, Blasinska-Morawiec M, Espinosa E, Villanova G.

Clin Breast Cancer. 2018 Feb;18(1):e41-e47. doi: 10.1016/j.clbc.2017.05.012. Epub 2017 Jun 27.

PMID:
28666812
11.

Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myeloma.

Podar K, Pecherstorfer M.

Expert Opin Pharmacother. 2017 Aug;18(11):1061-1079. doi: 10.1080/14656566.2017.1340942. Epub 2017 Jul 5. Review.

PMID:
28604120
12.

Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial.

Greil R, Obrtlíková P, Smolej L, Kozák T, Steurer M, Andel J, Burgstaller S, Mikušková E, Gercheva L, Nösslinger T, Papajík T, Ladická M, Girschikofsky M, Hrubiško M, Jäger U, Fridrik M, Pecherstorfer M, Králiková E, Burcoveanu C, Spasov E, Petzer A, Mihaylov G, Raynov J, Oexle H, Zabernigg A, Flochová E, Palášthy S, Stehlíková O, Doubek M, Altenhofer P, Pleyer L, Melchardt T, Klingler A, Mayer J, Egle A.

Lancet Haematol. 2016 Jul;3(7):e317-29. doi: 10.1016/S2352-3026(16)30045-X. Epub 2016 Jun 16.

PMID:
27374465
13.

A single-center retrospective analysis of first-line therapy of multiple myeloma with bendamustine-bortezomib-dexamethasone.

Zwickl H, Zwickl-Traxler E, Pecherstorfer M.

Leuk Lymphoma. 2016 Sep;57(9):2065-70. doi: 10.3109/10428194.2015.1126587. Epub 2016 Feb 22.

PMID:
26901249
14.

Expert opinion 2011 on the use of new anti-resorptive agents in the prevention of skeletal-related events in metastatic bone disease.

Anghel R, Bachmann A, Bekşac M, Brodowicz T, Finek J, Komadina R, Krzemieniecki K, Lang I, Marencak J, von Moos R, Pecherstorfer M, Rordorf T, Vrbanec D, Zielinski C; American Society of Clinical Oncology; National Comprehensive Cancer Network.

Wien Klin Wochenschr. 2013 Aug;125(15-16):439-47. doi: 10.1007/s00508-013-0385-4. Epub 2013 Jul 6.

PMID:
23832237
15.

Treatment options for breast cancer and bone metastases.

Pecherstorfer M.

Womens Health (Lond). 2009 Mar;5(2):149-63. doi: 10.2217/17455057.5.2.149. Review.

PMID:
19245353
16.

[Bisphosphonates and osteonecrosis of the jaw--an increasing challenge in palliative care].

Beke D, Pecherstorfer M.

Wien Med Wochenschr. 2008;158(23-24):702-6. doi: 10.1007/s10354-008-0630-z. German.

PMID:
19165450
17.

Managing neoplastic bone disease with ibandronic acid: a preclinical and clinical data update.

Pecherstorfer M.

Expert Opin Pharmacother. 2008 Dec;9(17):3111-9. doi: 10.1517/14656560802482945 .

PMID:
19006482
18.

Renal safety profiles of ibandronate 6 mg infused over 15 and 60 min: a randomized, open-label study.

von Moos R, Caspar CB, Thürlimann B, Angst R, Inauen R, Greil R, Bergstrom B, Schmieding K, Pecherstorfer M.

Ann Oncol. 2008 Jul;19(7):1266-70. doi: 10.1093/annonc/mdn038. Epub 2008 Mar 11.

PMID:
18334511
19.

Pathophysiology, risk factors and management of bisphosphonate-associated osteonecrosis of the jaw: Is there a diverse relationship of amino- and non-aminobisphosphonates?

Diel IJ, Fogelman I, Al-Nawas B, Hoffmeister B, Migliorati C, Gligorov J, Väänänen K, Pylkkänen L, Pecherstorfer M, Aapro MS.

Crit Rev Oncol Hematol. 2007 Dec;64(3):198-207. Epub 2007 Sep 12. Review.

PMID:
17855108
20.

Long-term safety of intravenous ibandronic acid for up to 4 years in metastatic breast cancer: an open-label trial.

Pecherstorfer M, Rivkin S, Body JJ, Diel I, Bergström B.

Clin Drug Investig. 2006;26(6):315-22.

PMID:
17163265
21.

Bisphosphonate treatment does not affect serum levels of osteoprotegerin and RANKL in hypercalcemic cancer patients.

Zojer N, Brenner K, Beke D, Kudlacek S, Hawa G, Woloszczuk W, Hofbauer LC, Pecherstorfer M.

Anticancer Res. 2005 Sep-Oct;25(5):3607-12.

22.

Current management strategies for hypercalcemia.

Pecherstorfer M, Brenner K, Zojer N.

Treat Endocrinol. 2003;2(4):273-92. Review.

PMID:
15966562
23.

Efficacy and safety of ibandronate in the treatment of neoplastic bone disease.

Pecherstorfer M.

Expert Opin Pharmacother. 2004 Nov;5(11):2341-50. Review.

PMID:
15500381
24.
25.

Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer.

Body JJ, Diel IJ, Bell R, Pecherstorfer M, Lichinitser MR, Lazarev AF, Tripathy D, Bergström B.

Pain. 2004 Oct;111(3):306-12.

PMID:
15363874
26.

Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies.

Body JJ, Diel IJ, Lichinitzer M, Lazarev A, Pecherstorfer M, Bell R, Tripathy D, Bergstrom B.

Br J Cancer. 2004 Mar 22;90(6):1133-7.

27.

Comparison of Technetium-99m-MIBI imaging with MRI for detection of spine involvement in patients with multiple myeloma.

Mirzaei S, Filipits M, Keck A, Bergmayer W, Knoll P, Koehn H, Ludwig H, Pecherstorfer M.

BMC Nucl Med. 2003 Dec 11;3(1):2.

28.

Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate.

Pecherstorfer M, Steinhauer EU, Rizzoli R, Wetterwald M, Bergström B.

Support Care Cancer. 2003 Aug;11(8):539-47. Epub 2003 Jun 3.

PMID:
12783289
29.

Regional cerebral blood flow in patients suffering from post-traumatic stress disorder.

Mirzaei S, Knoll P, Keck A, Preitler B, Gutierrez E, Umek H, Köhn H, Pecherstorfer M.

Neuropsychobiology. 2001;43(4):260-4.

PMID:
11340366
30.

Biochemical markers of bone formation in patients with plasma cell dyscrasias and benign osteoporosis.

Woitge HW, Horn E, Keck AV, Auler B, Seibel MJ, Pecherstorfer M.

Clin Chem. 2001 Apr;47(4):686-93.

31.

Serum bone sialoprotein as a marker of tumour burden and neoplastic bone involvement and as a prognostic factor in multiple myeloma.

Woitge HW, Pecherstorfer M, Horn E, Keck AV, Diel IJ, Bayer P, Ludwig H, Ziegler R, Seibel MJ.

Br J Cancer. 2001 Feb 2;84(3):344-51.

32.

Effect of first treatment with aminobisphosphonates pamidronate and ibandronate on circulating lymphocyte subpopulations.

Pecherstorfer M, Jilch R, Sauty A, Horn E, Keck AV, Zimmer-Roth I, Thiebaud D.

J Bone Miner Res. 2000 Jan;15(1):147-54.

33.

Serum bone sialoprotein in patients with primary breast cancer is a prognostic marker for subsequent bone metastasis.

Diel IJ, Solomayer EF, Seibel MJ, Pfeilschifter J, Maisenbacher H, Gollan C, Pecherstorfer M, Conradi R, Kehr G, Boehm E, Armbruster FP, Bastert G.

Clin Cancer Res. 1999 Dec;5(12):3914-9.

34.

Comparative tolerability of drug therapies for hypercalcaemia of malignancy.

Zojer N, Keck AV, Pecherstorfer M.

Drug Saf. 1999 Nov;21(5):389-406. Review.

PMID:
10554053
35.

Serum parathyroid hormone-related protein levels and response to bisphosphonate treatment in hypercalcemia of malignancy.

Rizzoli R, Thiébaud D, Bundred N, Pecherstorfer M, Herrmann Z, Huss HJ, Rückert F, Manegold C, Tubiana-Hulin M, Steinhauer EU, Degardin M, Thürlimann B, Clemens MR, Eghbali H, Body JJ.

J Clin Endocrinol Metab. 1999 Oct;84(10):3545-50.

PMID:
10522993
36.

Biochemical modulation of 5-fluorouracil by leucovorin with or without interferon-alpha-2c in patients with advanced colorectal cancer: final results of a randomised phase III study.

Hausmaninger H, Moser R, Samonigg H, Mlineritsch B, Schmidt H, Pecherstorfer M, Fridrik M, Kopf C, Nitsche D, Kaider A, Ludwig H.

Eur J Cancer. 1999 Mar;35(3):380-5.

PMID:
10448286
37.

Novel serum markers of bone resorption: clinical assessment and comparison with established urinary indices.

Woitge HW, Pecherstorfer M, Li Y, Keck AV, Horn E, Ziegler R, Seibel MJ.

J Bone Miner Res. 1999 May;14(5):792-801.

38.

Images in clinical medicine. Cutaneous melanoma metastases.

Pecherstorfer M.

N Engl J Med. 1997 Nov 13;337(20):1435. No abstract available.

39.

Bone resorption in multiple myeloma and in monoclonal gammopathy of undetermined significance: quantification by urinary pyridinium cross-links of collagen.

Pecherstorfer M, Seibel MJ, Woitge HW, Horn E, Schuster J, Neuda J, Sagaster P, Köhn H, Bayer P, Thiébaud D, Ludwig H.

Blood. 1997 Nov 1;90(9):3743-50.

PMID:
9345061
40.

Interphase fluorescence in situ hybridization improves the detection of malignant cells in effusions from breast cancer patients.

Zojer N, Fiegl M, Angerler J, Müllauer L, Gsur A, Roka S, Pecherstorfer M, Huber H, Drach J.

Br J Cancer. 1997;75(3):403-7.

41.

Serum immunoreactive bone sialoprotein as a new marker of bone turnover in metabolic and malignant bone disease.

Seibel MJ, Woitge HW, Pecherstorfer M, Karmatschek M, Horn E, Ludwig H, Armbruster FP, Ziegler R.

J Clin Endocrinol Metab. 1996 Sep;81(9):3289-94.

PMID:
8784085
42.

Administration of the bisphosphonate ibandronate (BM 21.0955) by intravenous bolus injection.

Pecherstorfer M, Ludwig H, Schlosser K, Buck S, Huss HJ, Body JJ.

J Bone Miner Res. 1996 May;11(5):587-93.

PMID:
9157773
43.

Glucocorticoids decrease the production of parathyroid hormone-related protein in vitro but not in vivo in the Walker carcinosarcoma 256 rat model.

Schilling T, Pecherstorfer M, Blind E, Kohl B, Wagner H, Ziegler R, Raue F.

Bone. 1996 Apr;18(4):315-9.

PMID:
8726387
44.

Interleukin-6 and tumor necrosis factor alpha levels after bisphosphonates treatment in vitro and in patients with malignancy.

Sauty A, Pecherstorfer M, Zimmer-Roth I, Fioroni P, Juillerat L, Markert M, Ludwig H, Leuenberger P, Burckhardt P, Thiebaud D.

Bone. 1996 Feb;18(2):133-9.

PMID:
8833207
45.

[Plasminogen activator inhibitor 1 and prognosis in breast carcinoma].

Mayerhofer K, Stolzlechner J, Yildiz S, Haider K, Heinzl H, Jakesz R, Pecherstorfer M, Rosen H, Sevelda P, Zeillinger R, Speiser P.

Geburtshilfe Frauenheilkd. 1996 Jan;56(1):23-7. German.

PMID:
8852782
46.

Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy.

Pecherstorfer M, Herrmann Z, Body JJ, Manegold C, Degardin M, Clemens MR, Thürlimann B, Tubiana-Hulin M, Steinhauer EU, van Eijkeren M, Huss HJ, Thiébaud D.

J Clin Oncol. 1996 Jan;14(1):268-76.

PMID:
8558208
47.

Recombinant human erythropoietin for the correction of cancer associated anemia with and without concomitant cytotoxic chemotherapy.

Ludwig H, Sundal E, Pecherstorfer M, Leitgeb C, Bauernhofer T, Beinhauer A, Samonigg H, Kappeler AW, Fritz E.

Cancer. 1995 Dec 1;76(11):2319-29.

PMID:
8635038
48.

The diagnostic value of urinary pyridinium cross-links of collagen, serum total alkaline phosphatase, and urinary calcium excretion in neoplastic bone disease.

Pecherstorfer M, Zimmer-Roth I, Schilling T, Woitge HW, Schmidt H, Baumgartner G, Thiébaud D, Ludwig H, Seibel MJ.

J Clin Endocrinol Metab. 1995 Jan;80(1):97-103.

PMID:
7829646
49.

pS2 protein status fails to be an independent prognostic factor in an average breast cancer population.

Speiser P, Stolzlechner J, Haider K, Heinzl H, Jakesz R, Pecherstorfer M, Rosen H, Sevelda P, Zeilliger R.

Anticancer Res. 1994 Sep-Oct;14(5B):2125-30.

PMID:
7840511
50.

Prediction of response to erythropoietin treatment in chronic anemia of cancer.

Ludwig H, Fritz E, Leitgeb C, Pecherstorfer M, Samonigg H, Schuster J.

Blood. 1994 Aug 15;84(4):1056-63.

PMID:
7741835

Supplemental Content

Loading ...
Support Center